Mandate

Vinge advises Isofol in connection with capital procurement

Vinge has advised Isofol Medical AB (publ), Nasdaq First North Premier Growth Market, in connection with a fully guaranteed rights issue and exercised over-allotment option which together add SEK 500 million to Isofol before transaction costs.

Vinge’s team primarily consisted of Anders StridEdin AgicJenny Sandlund and Beatrice Randow.

Related

Vinge advised Dr Schär

Vinge advised Dr Schär in the acquisition of Semper AB:s glutenfree business Dr. Schär, an Italian based company, is a developer of product for special nutritional needs.
February 29, 2024

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue
February 29, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").
February 29, 2024